| 2026-08-07 | Press release | ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results |
| 2026-08-07 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-07 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-24 | Press release | ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET |
| 2026-07-16 | Press release | ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter |
| 2026-07-13 | Press release | ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Tria |
| 2026-05-27 | Press release | ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference |
| 2026-05-21 | 8-K | Form 8-K, Item 5.02 |
| 2026-05-13 | 8-K | Form 8-K, Item 7.01 |
| 2026-05-08 | Press release | ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance |
| 2026-05-08 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-08 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-24 | Press release | ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET |
| 2026-04-20 | Press release | ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity |
| 2026-04-13 | Press release | ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules |
| 2026-04-09 | Proxy | Definitive proxy statement |
| 2026-04-08 | Press release | ANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate Tablet |
| 2026-04-07 | Press release | ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology |
| 2026-04-07 | 8-K | Form 8-K, Item 4.01 |
| 2026-03-03 | 8-K | Form 8-K, Item 7.01 |
| 2026-02-28 | Transcript | Q4 FY25 earnings call transcript |
| 2026-02-27 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-27 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-24 | Press release | ANI Pharmaceuticals to Present at Upcoming Investor Conferences |
| 2026-02-13 | Press release | ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on , at 8:00 a.m. ET |
| 2026-01-12 | Press release | ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Prio |
| 2026-01-12 | 8-K | Form 8-K, Item 2.02 results |
| 2026-01-06 | Press release | ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 2025-12-01 | 8-K | Form 8-K, Item 5.02 |
| 2025-11-10 | 8-K | Form 8-K, Item 2.02 results |
| 2025-11-07 | Press release | ANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 Guidance |
| 2025-11-07 | 8-K | Form 8-K, Item 2.02 results |
| 2025-11-07 | 10-Q | Form 10-Q for the quarter ended Sep 30 |
| 2025-10-24 | Press release | ANI Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 7, 2025, at 8:30 a.m. ET |
| 2025-09-26 | 8-K | Form 8-K, Item 3.02 |
| 2025-09-08 | 8-K | Form 8-K, Item 2.02 results |
| 2025-08-08 | Press release | ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance |
| 2025-08-08 | 8-K | Form 8-K, Item 2.02 results |
| 2025-08-08 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2025-08-08 | Transcript | Q2 FY25 earnings call transcript |